The New Drug Reimbursement Game

A Regulator’s Guide to Playing and Winning

Nonfiction, Health & Well Being, Medical, Specialties, Pharmacy, Medical Science, Pharmacology
Cover of the book The New Drug Reimbursement Game by Brita A.K. Pekarsky, Springer International Publishing
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: Brita A.K. Pekarsky ISBN: 9783319089034
Publisher: Springer International Publishing Publication: October 9, 2014
Imprint: Adis Language: English
Author: Brita A.K. Pekarsky
ISBN: 9783319089034
Publisher: Springer International Publishing
Publication: October 9, 2014
Imprint: Adis
Language: English

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation.  It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation.  The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. 

Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare.  The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price.   

The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated.  Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system.  Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price.  PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.  

 

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

This comprehensive text presents a rigorous framework from within which regulators can respond strategically to the claim by the pharmaceutical industry that lower drug prices today lead to a loss for the population’s future health due to less innovation.  It starts with a critical review of the empirical evidence of the return to consumers on their ongoing investment into high drug prices in order to increase future innovation.  The implicit, critical and unrealistic assumption inherent in these studies is identified, namely that the health budget can be expanded to purchase drugs at higher prices without an opportunity cost, for example, the foregone benefits of alternative investments in health care infrastructure. 

Price effectiveness analysis (PEA), is introduced. PEA informs the question of how the innovative surplus from the new drug should be allocated between the manufacturer and the consumer so as to optimise society’s welfare.  The method allows the decisions by the regulator and the firm to be analysed jointly by specifying the firm’s production and revenue functions in terms of the clinical innovation of a new drug; the incremental effect used in the summary metric of cost effectiveness analysis. An economic value of innovation that takes into account opportunity cost under conditions of economic efficiency in the health system is proposed: the health shadow price.   

The limitations of the non-strategic methods that currently inform the highly contested new drug subsidy game are presented and the relative strengths of PEA are demonstrated.  Health technology assessment quantifies both the clinical innovation of a new drug and its financial impact on the health system.  Cost effectiveness analysis tests the relationship between the incremental cost and incremental effect of a new drug for target patients, at a given price.  PEA tests the relationship between the price of a new drug and the health of the whole population, now and into the future. It achieves this by taking into account current inefficiency in both resource allocation and the displacement process, and the relationship between price and future innovation.  

 

More books from Springer International Publishing

Cover of the book Virtual Reality and Augmented Reality by Brita A.K. Pekarsky
Cover of the book Musculoskeletal Research and Basic Science by Brita A.K. Pekarsky
Cover of the book Geometric and Numerical Foundations of Movements by Brita A.K. Pekarsky
Cover of the book Geography Education for Global Understanding by Brita A.K. Pekarsky
Cover of the book Effect of Milk Fat Globule Size on the Physical Functionality of Dairy Products by Brita A.K. Pekarsky
Cover of the book Biology of Orthodontic Tooth Movement by Brita A.K. Pekarsky
Cover of the book Computer Vision – ECCV 2016 Workshops by Brita A.K. Pekarsky
Cover of the book Contemporary Trends in Accounting, Finance and Financial Institutions by Brita A.K. Pekarsky
Cover of the book Human Centered Computing by Brita A.K. Pekarsky
Cover of the book Cohesive Subgraph Computation over Large Sparse Graphs by Brita A.K. Pekarsky
Cover of the book Arithmetic of Finite Fields by Brita A.K. Pekarsky
Cover of the book Evolutionary and Deterministic Methods for Design Optimization and Control With Applications to Industrial and Societal Problems by Brita A.K. Pekarsky
Cover of the book Trends in Cyber-Physical Multi-Agent Systems. The PAAMS Collection - 15th International Conference, PAAMS 2017 by Brita A.K. Pekarsky
Cover of the book New Technologies, Development and Application by Brita A.K. Pekarsky
Cover of the book Complications of Temporomandibular Joint Surgery by Brita A.K. Pekarsky
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy